A study to assess the feasibility of decreased duration of treatment in bladder cancer in Indian setting

Hypo-fractionated Radical radiotherapy in Muscle Invasive Bladder Cancer: A Feasibility Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/047509

Enrollment

Registered

2022-11-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C679- Malignant neoplasm of bladder, unspecified

Interventions

Intervention1: Radiation therapy: Radiotherapy dose: 55Gy in 20 fractions over 4 weeks As this is a single arm study, comparator agent is not applicable Intervention2: Radiation therapy: Radiotherapy

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven muscle-invasive bladder cancers with/ without clinically positive pelvic and paraaortic lymph nodes on imaging 2. No distant visceral or bony metastases 3. Planned for definitive radiotherapy with or without concurrent chemotherapy [Medically inoperable, refuses surgery]

Exclusion criteria

Exclusion criteria: 1. History of prior radiotherapy to the pelvis 2. Pregnant or lactating women 3. Poor ECOG performance status [3/4]

Design outcomes

Primary

Measure	Time frame
To assess the feasibility and early toxicity of radical hypo-fractionated radiotherapy with or without concurrent chemotherapy in patients with non-metastatic muscle invasive bladder cancers.Timepoint: 3 months of completion of radiation therapy	—

Secondary

Measure	Time frame
To assess locoregional controlTimepoint: 1 year	—

Countries

India

Contacts

Public ContactKannan Periasamy

PGIMER

pkannan10011988@gmail.com9442395508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026